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Stem cells: novel players in the treatment of erectile
dysfunction
Haiyang Zhang1,2, Maarten Albersen3, Xunbo Jin1 and Guiting Lin2
Stem cells are defined by their capacity for both self-renewal and directed differentiation; thus, they represent great promise for
regenerativemedicine. Historically, stem cells have been categorized as either embryonic stem cells (ESCs) or adult stem cells (ASCs).
It was previously believed that only ESCs hold the ability to differentiate into any cell type, whereas ASCs have the capacity to give rise
only to cells of a given germ layer. More recently, however, numerous studies demonstrated the ability of ASCs to differentiate into cell
types beyond their tissue origin. The aim of this review was to summarize contemporary evidence regarding stem cell availability,
differentiation, and more specifically, the potential of these cells in the diagnosis and treatment of erectile dysfunction (ED) in both
animal models and human research. We performed a search on PubMed for articles related to definition, localisation and circulation of
stem cells as well as the application of stem cells in both diagnosis and treatment of ED. Strong evidence supports the concept that
stem cell therapy is potentially the next therapeutic approach for ED. To date, a large spectrum of stem cells, including bone marrow
mesenchymal stem cells, adipose tissue-derived stemcells andmuscle-derived stem cells, have been investigated for neural, vascular,
endothelial or smooth muscle regeneration in animal models for ED. In addition, several subtypes of ASCs are localized in the penis,
and circulating endogenous stem cells can be employed to predict the outcome of ED and ED-related cardiovascular diseases.
Asian Journal of Andrology (2012) 14, 145–155; doi:10.1038/aja.2011.79; published online 17 October 2011
Keywords: adipose tissue-derived stem cells; bone marrow stem cells; erectile dysfunction; mesenchymal stem cells; stem cells
INTRODUCTION
Stem cells are by definition capable of self-renewal, meaning that they
canmake exact copies of themselves indefinitely, and of differentiation
into a variety of phenotypes.1,2 They have been shown to be able to
functionally regenerate damaged tissues, depending on the stimuli or
signals that they receive.1,2 When a stem cell divides, both daughter
cells have the potential either to remain stem cells or to become amore
specialized type of cell, such as a muscle cell, a red blood cell or a brain
cell. Stem cells are classified into totipotent, pluripotent, multipotent
and unipotent in a hierarchal order based on the number of cell
lineages to which they may potentially differentiate.3 Totipotent stem
cells, like the zygote and its offspring cells of the morula, have the
greatest differentiation potential and are capable of forming cells of
the ectoderm, mesoderm and endoderm.4 Pluripotent stem cells give
rise to the three germ layers, but not to extra-embryonic tissues.
Embryonic stem cells (ESCs), isolated from the inner cell mass of
blastocysts,5 are the most widely acknowledged example of pluripo-
tent cells.6 Multipotent stem cells, such as haematopoietic stem cells
(HSCs) andmesenchymal stem cells (MSCs) , isolated from the devel-
oping germ layer and their descended adult organs, are capable of self-
renewal, and they can differentiate into any cell type within their germ
layer.4 Unipotent cells are progenitor cells or precursor cells with a
limited capacity for self-renewal, and they can differentiate into only
one defined cell type, such as epithelial cells.4,7
Harvesting ESCs requires the destruction of human embryos and
has raised significant ethical and political concerns. These barriers
have prompted the search for alternative stem cell sources, including
amniotic fluid-derived stem cells and adult stem cells (ASCs).7 ASCs
are gaining popularity, as researchers are finding a more extensive
differentiation potential than was previously thought to exist, with
some studies demonstrating pluripotency of certain ASCs.8,9
Erectile dysfunction (ED) is defined as the inability to attain and
maintain an erection with sufficient rigidity to permit satisfactory
sexual intercourse.10 Vascular diseases, which are correlated with
smoking, aging, hyperlipidemia, diabetes and hypertension, are major
causes of ED. Injury to the cavernous nerves during pelvic surgery,
such as radical prostatectomy, comprises an appreciable number of
ED cases as well.6 Other causes of ED include direct trauma to the
genitals, endocrine disorders, and fibrosis of the penile vasculature
and corporal smooth muscle.11 The aetiological theme linking both
vasculogenic and neurogenic ED is the loss of normal cellular function
or death of the cells themselves.
While oral pharmacotherapies, such as phosphodiesterase-5 inhi-
bitors (PDE5is), have clear benefits, their actions are necessarily eph-
emeral, and treatment is relatively costly.6 Furthermore, they do not
provide a cure, and a number of patients have tissue damage that is so
extensive that the response to either oral or local pharmacotherapy is
minimal. Consequently, researchers have been investigating stem cells
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as a substitute therapeutic strategy. Compared with other fields, the
application of cell-based therapy for ED is relatively new.12 The poten-
tially curative nature of stem cells recently prompted a number of
studies with varying stem cell populations and strategies.6 Currently,
it appears to be one of the most studied potential future treatments of
ED.
STEM CELL SOURCES, THEIR LOCATION AND CIRCULATION
Stem cells and sources
Currently, there are three ways to obtain a pluripotent stem cell,
including ESC isolation, somatic cell nuclear transfer and somatic cell
reprogramming. In 1981, pluripotent ESCs were first discovered in the
inner cell mass of the mouse embryo.13 Their ability to differentiate
into many cell types aroused tremendous hope for their potential
application in cell therapy and regenerative medicine. However, as
stated above, ESCs present an ethical burden. To overcome this lim-
itation, new stem cell technologies, such as the induction of pluripo-
tency by somatic cell nuclear transfer and reprogramming, have been
established.7 Over the past few years, the successful generation of
induced pluripotent stem cells (iPSCs) brought about new hope for
regenerative therapies.14 Many groups have now shown that somatic
cells can be reprogrammed by overexpression of variable sets of few
transcription factors in cells that share various characteristics with
ESCs.14–17 To date, several novel reprogramming protocols are avail-
able,18–22 which have broadened the spectrum of cell types and species
involved in iPSCs generation. Similar to ESCs, iPSCs also show the
potential for differentiation into numerous cell types. However, the
degree of molecular similarity between iPSCs and ESCs has not been
completely elucidated. To date, it is not clear whether these small
differences are the result of interexperiment variability or whether
reprogramming of somatic cells generates a state that is unique to
ESCs.23 Thus, iPSCs seem to hold promise for regeneration medicine
once ascribed solely to ESC.
To avoid ethical dilemmas, ASCs have been given increasing atten-
tion. ASCs tend to be tissue specific, self-renewing populations of cells
that can differentiate into cell types associatedwith the organ system in
which they reside.24–26 While they used to be considered multipotent
at the most, a continuously expanding body of literature suggests that
certain ASCs appear to possess pluripotent differentiation capacity.2
ASCs are easily identified in tissues with high cell turnover.Within the
last decade, many niches of ASCs were discovered in many tissues,
such as the brain, liver, skin, skeletal muscle, the gastrointestinal tract,
adipose tissue, pancreas, eye, blood and dental pulp.24–28 Among
them, the most notable exception to the tissue specificity of ASCs
are the MSCs, which are defined as (multipotent) MSCs. They are
capable of differentiating in vitro into various mesenchymal/mesoder-
mal cells and differentiating developmentally if injected into a blasto-
cyst.26 MSCs have been extensively tested and proven effective in
preclinical studies, and they currently are being tested in US FDA-
approved clinical trials for the treatment of myocardial infarction,
stroke, meniscus injury, limb ischemia, graft-versus-host disease and
autoimmune disorders.29 Although the mechanisms are not comple-
tely clear, MSCs are known to secrete a broad range of cytokines and
growth factors that have both paracrine and autocrine effects on
damaged tissues.MSCs have been isolated from bonemarrow, adipose
tissue, skeletal muscle, dental pulp and cord blood.30–34 Among them,
the most studied are bonemarrow-derived stem cells (BMSCs), which
are derived from bonemarrow stroma (hence their name). In the early
1960s, BMSCs were first determined to be responsible for marrow
reconstitution due to their ability to renew themselves and their ability
to differentiate into various cell types.35,36 Recently, MSCs derived
from the stromal vascular fraction of adipose tissue, termed as adipose
tissue-derived stem cells (ADSCs), represent an abundant and easily
accessible source of stem cells.37 While bone marrow is obtainable in
the gram range by a painful marrow aspiration procedure, adipose
tissue can be obtained in the range of hundreds of grams with a
minimally invasive procedure. The possibility of harvesting hundreds
of grams of adipose tissue excludes the need for MSC isolation and
culture steps and allows for the direct re-injection of the stromal
vascular fraction during the same surgical procedure in which they
were harvested. ADSCs bear a strong resemblance to BMSCs, as
demonstrated by the expression of common cell surface markers, sim-
ilar gene expression profiles and similar differentiation potentials.
Therefore, it is reasonable to expect that ADSCs will become the pre-
ferred choice of ASCs for future clinical applications.37
Localisation of ASCs in their native tissue—stem cell niche
The stem cell niche is a microenvironment that maintains stem cells in
a quiescent state. After tissue injury, the niche promotes either self-
renewal or differentiation to form new tissues.38 Several components
of this microenvironment regulate stem cell characteristics within the
niche: cell–cell interactions between stem cells and other stem cells or
neighbouring differentiated cells; interactions of stem cells with adhe-
sion molecules and the extracellular matrix; the presence and active
secretion of a multitude of cytokines and growth factors; and oxygen
tension and other physiochemical determinants. The stem cell niche is
often located in the perivascular space of various tissues, thus provid-
ing direct access to the systemic circulation into which endogenous
stem cells are recruited during tissue injury. In spite of the perivascular
location of the niche, this microenvironment appears to be in a con-
tinuous state of relative hypoxia.39,40 For example, the mesenchymal
stem cell niche is exposed to oxygen tension as low as 2%.40 The latter
finding has driven researchers to culture stem cells in hypoxic condi-
tions, thereby replicating their physiological environment. It has been
shown that various stem cells may benefit from these culture condi-
tions, replicating the niche in vitro: there have been observations of
increased growth factor secretion and increased engraftment potential
after hypoxic culturing.41
The niche supports stem cell activity through complex but not
completely known mechanisms, including: (i) the secretion of soluble
factors, such as growth factors and cytokines;41 (ii) a strong interaction
and self-renewal potential between stem cells and their niches; for
example, hair follicle bulge stem cells expanded in culture and grafted
into nude mice generated new bulge niches;42 and (iii) the activation
of a variety of signals and cytokines when stem cell reinforcements are
needed for tissue repair or regeneration, transforming the niche from a
resting place to a command centre.43–45
There are two classic types of stem cell niches based on their ana-
tomic relationship to stem cells:38 the stromal type and the epithelial
type:
1. Stromal type. Niche cells reside in close proximity to their respect-
ive stem cell pools. For example, many HSCs and BMSCs reside
along the endosteal surface of trabecular bone in close proximity
to both bone-forming osteoblasts and vascular endothelial cells
(ECs)46–48 (Figure 1a), the latter of which may facilitate mobili-
sation of stem cells from bone marrow into the circulation and
their return to these niches.49 During the last few years, the vas-
cular wall has been considered as an important reservoir for dif-
ferent types of stem and progenitor cells;50,51 in addition, many
kinds of stem cells, including ADSCs, HSCs, neural stem cells
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(NSCs), intestinal stem cells and spermatogonial stem cells,37,52–55
have been discovered by culturing stromal vascular fractions from
their respective native tissue. Generally, perivascular cells, including
pericytes in capillaries and adventitial cells around larger vessels,
are considered to be able to originate multilineage mesodermal
progenitor cells (Figure 1c).50
2. Epithelial type. The most typical example of this type resides
within a specialized region of the outer root sheath of the hair
follicle and is known as the follicular bulge stem cell niche. The
stem cells in this niche could give rise to newmatrix cells located at
the base of the hair and adjacent to the dermal papilla that support
hair growth56 (Figure 1b).
Trafficking of exogenously administered stem cells
In the clinical setting, the administration route of stem cells depends
on the anatomy and the extent of damage of the involved tissue or
organ, offering a choice between two approaches: direct local
implantation versus systemic intravascular administration.57 Local
implantation is an invasive procedure that could also disrupt the
highly complex and delicate microenvironment, causing inflam-
mation and multifocality of many disorders.57 Therefore, systemic
diseases rely on vascular delivery of stem cells. However, the thera-
peutic efficacy depends on ensuring that sufficient stem cells home to
the bone marrow or mobilize from the bone marrow to the damaged
area. Homing is thought to be a multistep process that involves:
(i) signalling and chemoattraction by chemokines; (ii) activation
and attachment to adhesion molecules on the endothelial cell surface;
and (iii) transendothelial migration of the stem cells into the diseased
tissue.
Chemokines are a family of small cytokines. Their name is derived
from their ability to induce directed chemotaxis in nearby responsive
cells. Some chemokines are considered pro-inflammatory and can be
induced during an immune response to recruit cells of the immune
system to a site of infection. While most chemokines are important
mediators of inflammation, it was recently discovered that chemokine
secretion in sites of tissue damage or inflammation can be used to
direct regenerative therapy.58 More specifically, certain types of stem
cells have been shown to express mRNA and a large number of
chemokine-receptors. Various groups have shown expression of the
chemokine stromal cell-derived factor 1a (CXCL12) in myocardial
infarction;59 CX3CL1, CCL2, CCL3 and CCL5 in peripheral neural
injury;60 and CCL7 in rat models of birth injury and stress urinary
incontinence.61 Recent data indicate that CXCL12 may play a role in
trafficking ADSCs towards the major pelvic ganglion in rats with an
injured cavernous nerve.62 In our laboratory, we have performed a
comparative analysis between ADSCs and BMSCs and were able to
show that these two types of MSCs express a similar panel of chemo-
kine receptors. We identified expression of mRNA for 12 of the cur-
rently known 21 chemokine receptors, and found that these receptors
were located both on the cell surface as well as intracellularly, suggest-
ing that chemokine receptors are recycled in these stem cells, as has
been previously shown in various immune cells (unpublished data).
What the exact role of these chemokine receptors is in homing towards
sites of tissue injury and what effects this stem cell recruitment has on
the host tissue remains largely unknown and is the focus of intense
investigation in stem cell biology.
After the recruitment of stem cells towards the injured tissue by
chemoattraction, the activation of lymphocyte function-associated
antigen 1, very late antigen 4/5 and CD44, cytoskeleton rearrange-
ment, membrane type 1-matrix metalloproteinase activation and the
secretion of matrix metalloproteinase-2/9 play important roles in the
interaction between stem cells and endothelial cells.58–63 Rolling and
firm adhesion is followed by transendothelial migration across the
physical endothelium/extracellular matrix barrier.
Similar processes play a role in homing of stem cells towards their
niche from the circulation. Chemoattraction, mainly by CXCL12,
adhesion to the endothelium and transendothelial migration are com-
parable to those processes in injured tissues. In the last stage, stem cells
finalize their ‘homing’ by anchorage to their specialized niches in
the extravascular space of the endosteum region and at perivascular
sites.60
Reawakening and mobilisation of endogenous stem cells
The development of techniques to reawaken andmobilize endogenous
pools of stem cells would represent progress in the field of regenerative
Figure 1 Stem cells niches. (a) Stromal type. HSCs are found adjacent to sinusoidal blood vessels as well as at or near the endosteum. Ostoblasts and mesenchymal
progenitors have been proposed to produce factors that regulate HSC maintenance. (b) Epithelial type. Stem cells located within the bulge region of the hair follicle give
rise to new matrix cells located at the base of the hair and adjacent to the dermal papilla that supports hair growth. Bulge cells can also help maintain the sebaceous
gland and the epidermal stem cells. (c) The vascular wall as a reservoir for stem and progenitor cells. Capillaries are constructed by endothelial cells lining the lumen
and pericytes, which cover the endothelial tube. Vascular wall-resident endothelial progenitor cells, HSCs and MSCs, are localized in the subendothelial space and are
probably located between or around pericytes. HSCs, haematopoietic stem cells; MSCs, mesenchymal stem cells.
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medicine. In general, the recruitment of HSCs from bonemarrow into
blood is termed ‘mobilisation’.64 This is a complex mechanism that
has not yet been clarified. The haematopoietic niche of the bone mar-
row expresses a broad array of cell surface receptors, such as the CXC
chemokine receptors CXCR4 and CXCR2, lymphocyte function-
associated antigen 1, very late antigen 4 and glycoprotein CD44,
among others.65 Data from a number of preclinical models showed
that the inhibition of these receptor–ligand interactions resulted in
enhanced progenitor cell mobilisation.66–68 Among them, CXCL12/
CXCR4 interactions may play key role in the regulation of the routine
and active egress of progenitor and maturing cells from the marrow
into the blood.64 Plerixafor, a novel agent that disrupts the CXCR4–
CXCL12 bond, which is the primary haematopoietic stem cell anchor
in the bone marrow, has recently been US FDA-approved for mobil-
izing HSCs from the bone marrow. Another common mobilisation
strategy in current clinical applications includes the use of cytokines
alone or in conjunction with chemotherapy.65 The currently available
cytokines include granulocyte colony-stimulating factor, granulocyte
macrophage colony-stimulating factor, and erythropoietin and recom-
binant methionyl human stem cell factor.65
PENILE STEM CELLS (PSCS)
Many types of ASCs have been reported in different tissues. In this
review, we will focus on the male erectile organ, the penis. As an organ
composed ofmultiple types of tissues, the penis itself contains a variety
of stem cells. To date, few types of penile stem cells have been isolated
or identified.
Foreskin stem cells
Two types of foreskin stem cells have been isolated to date, including
skin-derived progenitors (SKPs) and MSCs. A new and unique multi-
potent progenitor cell population from adult mammalian dermis,
termed SKPs, has been isolated and expanded from rodent and human
skin and differentiated into both neural andmesodermal progeny.69,70
SKPs did not apparently produce keratinocytes, distinguishing them
from epidermal stem cells. These progenitor cells have been reported
to reside in the dermal papillae of hair follicles.71When the skin cells of
neonatal and adult rodents were dissociated to single cells and grown
in suspension culture in the presence of the mitogens fibroblast
growth factor (FGF) and epidermal growth factor, floating spheres
of proliferating cells were generated.69 These spheres were positive
for nestin, a filament mainly expressed in neural and skeletal muscle
progenitors. Moreover, differentiation of SKPs in vitro resulted in the
generation of separate subpopulations of cells expressing neuronal,
glial, smooth muscle and adipocyte markers. In 2005, SKPs from
neonatal human foreskin tissue were identified,72 and they showed
similar biological characteristics to the animal cells mentioned above.
Because human neonatal foreskin does not contain hair follicles, the
presence of SKPs in foreskin provides evidence for an extrafollicular
SKP niche.72 However, the difficulty of reliably isolating and expand-
ing comparable populations of SKPs from both whole hairless and
hairy adult human skin suggests that this extrafollicular niche may
be significantly limited after the neonatal period in humans.70,71
Meanwhile, MSCs were also obtained from low-temperature pre-
served human foreskin biopsies by adherent culture.73 These cells
could differentiate into mesodermal lineages, including adipocytes,
osteocytes and myocytes.74 MSCs were antigenically distinct from
SKPs, and when grown under the same conditions, the MSCs grew
adherently (plastic adherence is one of the three hallmarks of MSCs),
while SKPs grew as floating spheres.
Tunica albuginea stem cells
Vernet and colleagues75 investigated whether cultures of cells from
normal tunica albuginea and Peyronie’s disease plaques undergo
osteogenesis, express markers of stem cells, and originate other cell
lineages via processes modulated by transforming growth factor-b1.
They found that both cultures express the stem cell marker CD34
and the SMCs markers smoothelin and transgelin. Cells expressing
CD34 and Sca-1 were also found in vivo in the normal tunica
albuginea, as well as in the corpora cavernosa.76 They were iden-
tified as potential endogenous stem cells because they are likely the
ones that, in the in vitro models, undergo multiple lineage differ-
entiation, and in the Peyronie’s disease plaque, they may convert
into myofibroblasts and osteoblasts. In addition, shaft penile tissue
sections from the rat and wild type mouse were immunostained for
Oct-4, an ESC marker.77 Results showed that Oct-41 cells were
detected in tunical and corporal tissues and that they could differ-
entiate into SMCs, myofibroblasts and cardiomyocytes. This is the
first report of the isolation and characterisation of embryonic-like
endogenous stem cells in penile tissues.
Perivascular stem cells
Although perivascular stem cells have been extracted from multiple
organs, such as bone marrow, dental pulp, placenta, fat and umbilical
cord,51 the penis, as a part of a systematic circulation tree, has not yet
received attention in this regard. We hypothesize that a ubiquitous
reserve of multilineage progenitor cells in the capillaries, veins and
arteries of the penis exists.
Endothelial progenitor cells (EPCs)
ED, cardiovascular disease and male hypogonadism share the com-
mon denominator of endothelial dysfunction, which has a well-
established role in the pathogenesis of both atherosclerosis and plaque
instability.78–80 One of the most exciting discoveries in vascular bio-
logy came in 1997 with the apparent detection of bone marrow-
derived EPCs,81 which have the capacity tomigrate into the peripheral
circulation and to differentiate into mature ECs, thus providing a
circulating pool of the cells thatmay contribute to ongoing endothelial
repair.82 This process, called vasculogenesis,83 is impaired in ED, as
documented by low levels of circulating EPCs.82 Meanwhile, at least
one research group believes that EPCs are native inhabitants of certain
blood vessel walls, and it would be instructive to determine whether
EPCs are embedded within the penile vasculature and can be stimu-
lated to repair dysfunctional penile ECs.84
Recently, several groups demonstrated that in ED patients, the
reduced level of EPCs could be restored by administration of
PDE5i,85,86 such as vardenafil and tadalafil, resulting in an effective
vasculoprotection and prevention of the initiation and progression of
endothelial dysfunction. Themechanisms remain unknown; however,
a possible hypothesis involves the presence of PDE5 in bone marrow
that, when inhibited, may magnify the local effect of nitric oxide, thus
leading to the mobilisation of stem and progenitor cells.85
APPLICATION OF STEM CELLS FOR PREDICTING ED
EPCs show a wide heterogenic antigenic profile, including expression
of CD34, CD133 and KDR. CD34 is an adhesion molecule expressed
onHSCs and is typically considered amarker of immaturity; CD133 is
a surface antigen of unknown function that identifies more immature
progenitor cells than CD34 alone; and KDR represents the type 2
vascular endothelial growth factor (VEGF) receptor and indicates
early endothelial differentiation.87
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There are several types of circulating EPCs related to ED. In par-
ticular, circulating levels of CD341CD1331 cells were recently shown
to be decreased in patients with EDwith or without cardiovascular risk
factors,82 while CD341KDR1 cells showed no relationship with ED.88
Meanwhile, increased levels of osteocalcin1 EPCs could be a pre-
dictive marker of subsequent coronary artery disease as well as ED.89
An increasing number of authors have described a population of EPCs
expressing osteocalcin, a typical osteo-related protein.90 Carlo’s
group89 investigated the correlation between osteocalcin1 EPCs and
cavernous atherosclerotic lesions in ED patients. They found that
osteocalcin1 EPC levels increased significantly with cavernous ather-
ogenesis progression.
We should note that decreased levels of EPCs are not specific indi-
cators for ED. Cardiovascular risk factors are known to decrease EPCs
with a subsequent increase of cardiovascular events and cardiovascular
deaths.91 Thus, circulating levels of EPCs are thought to be a link
between cardiovascular risk factors and endothelial dysfunction, with
a potential influence on erectile function.
APPLICATION OF STEM CELLS AS A THERAPY OF ED
Current pharmacological agents for vasculogenic ED, such as PDE5i,
lack efficacy in treating ED patients with advanced diabetes or patients
suffering from ED following radical prostatectomy.92,93 In the latter
condition, Wallerian degeneration of the nerve and target apoptosis
and fibrosis in the corpus cavernosum result in an irreversible loss of
function.6,94 Stem cell-based therapy has been proposed in the man-
agement of ED by complete replacement of lost or damaged cells or by
protecting threatened host cells via immunomodulatory effects, the
provision of trophic factors or gene delivery.95 In recent years, a num-
ber of reports related to the progress of stem cell-based ED therapy
have been published. Different therapeutic forms of stem cells have
been developed, includingmultiple sources of stem cells or progenitor
cells, gene-transfected stem cells, stem cell lysates and stem cells seeded
on tissue matrices (Table 1).
While some of the more extravagant claims are excessively optim-
istic, there is clear validity to the notion that stem cells may lead to
novel and potentially curative therapies. Nonetheless, clinical applica-
tion is a long way off. Prior to clinical use of stem cells, it will be
necessary to thoroughly investigate the malignant potential of stem
cells, especially for ESCs. Although ASCs seem to be more stable than
ESCs and are not as prone to forming tumours, many studies have
observed that ASCs can also form malignant tumours when trans-
planted in vivo.96 Another consideration is the rejection of allogeneic
stem cells by the host immune system.97 The use of ASCs and tissues
derived from the patient’s own ASCs wouldmean that the cells are less
likely to be rejected by the immune system. This represents a signifi-
cant advantage, as immune rejection can be circumvented only by
continuous administration of immunosuppressive drugs, and the
drugs themselves may cause deleterious side effects. To date, nine
different types of stem cells have been reported in the therapy of ED
in the laboratory.
BMSCs
The preclinical applications of BMSCs in treating ED were initially
based on their capacity to home to damaged tissues, differentiate into
the necessary mature phenotypes, and their amenability to genetic
manipulation.6,98
In 2003, Deng et al.99 demonstrated successful adenoviral gene
transfer of endothelial nitric oxide synthase (eNOS) to ex vivo
expanded rat BMSCs. The transfected BMSCs expressed high levels
of eNOS that persisted in culture for more than 21 days. The cells
retained their multipotential differentiation capability after transduc-
tion. Moreover, intracavernous injection of eNOS-BMSCs increased
the expression of eNOS in the corpus cavernosum and improved
erectile function in aged rats.
In 2007, it was shown that rat BMSCs were able to reverse age-
associated ED both with and without eNOS transfection through
mechanisms involving increased penile eNOS, improved eNOS/
cGMP signalling, and apparent differentiation into penile cells expres-
sing endothelial and smooth muscle markers.100 It also has been sug-
gested that human BMSCs are capable of differentiating toward ECs
and SMCs in the corpus cavernosum of rats.101 However, the efficacy of
these cells for the treatment of penile erectile function should be con-
firmed in immunocompromised animals because human stem cells are
not compatible in non-immunocompromised animals. In addition,
although a broad differentiation potential of BMSCs has been observed,
it may also be explained as the result of spontaneous fusion of host and
donor cells;102,103 therefore, it is difficult to prove the differentiation.
In 2010, Kendirci and colleagues104 showed that transplantation of
BMSCs isolated with p75 nerve growth factor (NGF) receptor into the
rat penis could rescue erectile function following cavernous nerve
injury. The authors suggested that these effects were mediated by
FGF, NGF, brain-derived neurotrophic factor (BDNF), VEGF and
insulin-like growth factor 1 (IGF-1) secreted by the stem cells. In a
rat model of diabetes mellitus type 1, Qiu et al.105 indicated that
transplantation of BMSCs restored erectile function by increasing
the content of endothelium and smooth muscle in the corporal caver-
nosum, though they did not study the paracrine action of transplanted
BMSCs or fusion between BMSCs and host smooth muscle cells or
endothelial cells. For age-associated ED, BMSC transplantation
improved erectile function during a long follow-up by improving
eNOS/cGMP signalling and, potentially, by also differentiation into
ECs and SMCs.106 In 2011, a study suggested that VEFG-gene-modified
BMSCs resulted in enhanced regeneration of smooth muscle and endo-
thelium in the corpora cavernosa of type I diabetic rats.107 The efficacy
and safety of BMSC treatment over a long duration needs to be inves-
tigated. Unexpected side effects of VEGF caused by angiogenesis, such as
angioma formation, may occur in a clinical trial.108 Thus, the possible
side effects of VEGF need to be assessed before a clinical trial is
conducted.
It is worth emphasizing that BMSCsmay not simply act by replacing
lost or damaged cells. The provision of trophic factors may protect
threatened cells from disease or stimulate proliferation of host pro-
genitors. Meanwhile, they could act independently to alter the
immune response to limit damage and promote repair and regenera-
tion; thus, their immunomodulatory effects have been employed clin-
ically in the treatment of graft-versus-host disease.109 It remains
controversial which mechanism plays the main role; however, an
increasing number of observations support the hypothesis that
BMSCs exert their effects on the host tissue by paracrine mechan-
isms.104 The beneficial effects of BMSCs in other animal models have
been observed within 3 days following transplantation, a time frame
that is too small to allow for engraftment and differentiation.104
Additionally, and perhaps most striking, the beneficial effects of
BMSCs have been replicated using cell-free lysates and conditioned
BMSC culture medium.110,111
Muscle-derived stem cells (MDSCs)
MDSCs are ASCs found inmuscle tissues. They are easily isolated from
autologous muscle biopsies, and they pose low immunogenic and
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Table 1 Application of stem cells for the therapy of erectile dysfunction
SCs type SCs form Model system Study
duration
Functional results Histology and molecular results
Rat BMSCs102 Cell (gene modified
with eNOS)
Aged rats 3 weeks Enhanced ICP during CN electrostimulation.
Better enhancement when combined with
eNOS gene therapy
Enhanced eNOS expression, and cGMP
levels. Transplanted cells exhibited
ECs and SMCs markers
Human BMSC103 Cell Young adult rats 2 weeks No functional testing. Transplanted cells exhibited ECs and
SMCs markers




4 weeks Enhanced ICP during CN electrostimulation.
Better enhancement for p75-derived BMSCs
p75-derived BMSCs secreted
significantly more basic NGF than
control group




4 weeks Enhanced ICP during CN electrostimulation.
Better enhancement when combined with
VEGF gene therapy
Increased content of smooth muscle
and endothelium in corporal
cavernosum. Transplanted cells
exhibited ECs and SMCs markers




Enhanced ICP during CN electrostimulation Increased percent area of PGP 9.5
staining




Enhanced ICP during CN electrostimulation in
aged rats (2 weeks) and young adult rats
(4 weeks)
Increased content of smooth muscle in
corporal cavernosum. Transplanted
cells exhibited SMCs markers
Rabbit MDSC114 ACCMs seeded with
MDSCs
Young adult rabbits 2 months,
4 months,
6 months
No functional testing Cells expressing ECs and SMCs markers
and better arranged growth were
prevalent




3 weeks Enhanced ICP during CN electrostimulation Enhanced neovascularisation in the
corpora cavernosum. Transplanted
cells exhibited ECs markers
Human UCBSCs 134 Cell Senior human with
DM II
11 months Regained morning erections in some patients.
Increased rigidity, but was insufficient for
penetration
No relevant testing
Rat ADSCs123 Cell Young adult rats 4 weeks No functional testing Injected ADSCs were localized to the
sinusoid endothelium. Some
Transplanted cells exhibited ECs
markers
Rat ADSCs126 Cell Young adult rats with
hyperlipid-emia
4 weeks Enhanced ICP during CN electrostimulation Increased content of smooth muscle
and endothelium in corporal
cavernosum, and nNOS-positive
nerve fibres in penile dorsal nerves
Rat ADSCs127 Cell Adult ZDF rats with
DM II
4 weeks Enhanced ICP during CN electrostimulation Increased nNOS staining area in penile
dorsal nerves. Inhibition of apoptosis
in corpus cavernosum
Rat ADSCs129 Cell and cell
lysate
Young adult rats with
CN crush
4 weeks Enhanced ICP during CN electrostimulation Increased content of smooth muscle in
corporal cavernosum, and nNOS-
positive nerve fibres in penile dorsal
nerves. Inhibition of fibrosis and
apoptosis
Human fetal NCSCs137 Cell Young adult rats 2 weeks No functional testing Transplanted cells exhibited ECs and
SMCs markers
Rat fetal BDSCs136 Cell Young adult rats 6 weeks No functional testing Transplanted cells exhibited SMCs
markers or VEGF
Rat GRPCs140 Cell Young adult rats with
spinal cord injury
12 weeks Preserved full and partial erectile
events per 24 h
GRPCs survived, differentiated and
formed extensive transplants that
were well integrated with host tissue
Rat neural ESCs141 Cell Young adult rats
with CN crush
12 weeks Enhanced ICP during CN electrostimulation Increased neurofilament staining in
the MPG and penile dorsal nerves.
Improved morphological characteristics
of nerve fibres in the corpora
cavernosum
Abbreviations: ACCMs, acellular corporal collagenmatrices; ADSCs, adipose tissue derived stem cells; BDSCs, brain-derived stem cells; BMSCs, bonemarrowmesenchymal
stem cells; CN, cavernous nerve; DM I, diabetes mellitus type I; DM II, diabetes mellitus type 2; ECs, endothelial cells; eNOS, endothelial nitric oxide synthase; EPCs,
endothelial precursor stem cells; ESCs, embryonic stem cells; GRPCs, glial restricted progenitor cells; ICP, intracavernous pressure; MDSCs, muscle-derived stem cells;
MPG,major pelvic ganglia; NCSCs, neural crest stem cells; nNOS, neuronal nitric oxide synthase; SCs, stemcells; SMCs, smoothmuscle cells; UCBSCs, umbilical cord blood
stem cells. PGP9.5, protein gene product 9.5; NGF, nerve growth factor; VEGF, vascular endothelial growth factor; ZDF, Zucker diabetic fatty.
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carcinogenic risks. Their enzymatic and non-enzymatic antioxidant
capacity provides them a critical property for MDSC survival post-
transplantation.112 This superior capacity supports their survival
advantages.
In 2006, MDSCs were first injected into the corpora cavernosum to
treat ED in rats with bilateral cavernous nerve injury.113 Although the
increase in PGP 9.5 neuronal staining suggested that the MDSCs pro-
tected the penile nerve from atrophy after cavernous nerve trans-
action, themechanisms need to be interpreted in the following studies.
In 2008, the ability of MDSCs to convert into SMCs after implanta-
tion into the corpora cavernosum of aged rats was reported.76
Exogenous MDSCs were able to correct ED, and endogenous cells also
expressed stem cell markers in the control group, suggesting that
exogenous stem cell implantation as well as endogenous stem cell
modulation may be viable therapeutic approaches for ageing-related
ED. Similar to BMSCs, when using the rat as a host, a truly allogenic
source of MDSCs has to be tested to eliminate the need for pharmaco-
logical immunosuppression. Moreover, the effects of MDSCs were
comparatively short-lived, and the considerable stimulation of erectile
function achieved at 2 weeks was reduced at 4 weeks. Therefore, addi-
tional research needs to be conducted to improve the survival of
MDSCs and ensure that the salutary functional effects could be pro-
longed for at least 3–6 months to exclude transient amelioration.
In 2010, acellular corporal collagen matrices seeded with MDSCs
were implanted within the albuginea of rabbits.114 Histological analyses
of the explants at all time points in the experimental group showed
more cells and improved arranged growth compared to the control
group. Alpha-smooth muscle actin and eNOS-positive cells were more
prevalent in the experimental group. As the authors mentioned in the
text, oxygen and nutrition were not available to MDSCs in the deeper
regions of the acellular corporal collagen matrices because of their
complex structure, resulting in some death of the transplanted
MDSCs. Thus, more suitable scaffold materials should be explored.
ADSCs
ADSCs isolated from the stromal vascular fraction of adipose tissue
have been recently identified and investigated for their multiple dif-
ferentiation properties.115 ADSCs share similar properties of other
stem cells, such as the ability to divide and renew themselves over long
periods of time and to differentiate into specialized cells. They are
much easier and safer to obtain in large quantities than BMSC,116
and, therefore, they appear to be a better choice for clinical application
for ED regeneration medicine.
In 2006, Ning et al.117 reported that ADSCs could be induced by
isobutylmethylxanthine to differentiate into neuron-like cells via the
IGF-1 signalling pathway.118 The significance of these studies is that
ADSCs possess the potential to treat degenerative neurological dis-
eases, including neurogenic ED.2
In 2008, a pilot experiment was conducted that demonstrated that
ADSCs improved the erectile function in the rat following bilateral
cavernous nerve crush injury.119 Several possible mechanisms under-
lying the treatment are proposed, including cell incorporation and
differentiation into native tissue cells versus paracrine signalling and
stimulation of the host tissue to regenerate, for instance, by secretion
of growth factors such as IGF-1 and GDF-5.116,120
In 2009, Ning et al.121 first reported that ADSCs could differentiate
into ECs in the penis and that this differentiation was mediated by
FGF2 signalling. Previously published experimental procedures for the
differentiation of ADSCs into ECs generally employed culture media
that contained VEGF, IGF or FGF2, and VEGF was assumed to be the
responsible factor.122 Interestingly, vitamin C was also found to be
essential for endothelial differentiation of ADSCs. Its role ismost likely
to promote the maintenance of a healthy growth environment for
endothelial cells by protecting them from oxidative stress.123
In 2010, a surge of reports concerning the application of ADSCs
as a therapy for ED was published. First, ADSCs were injected into
the penis to examine their effects on a rat model of hyperlipidemia-
associated ED; elevated erectile function was demonstrated after
ADSCs transplantation.124 An increase in neuronal nitric oxide
synthase (nNOS)-positive nerve fibres and ECs was observed in the
experimental group compared to the control animals. The authors
indicated that the underlying mechanisms involved cytokine and
growth factor secretion rather than stem cell differentiation.
However, they failed to indicate the specific growth factors. Another
critical question is the long-term safety of ADSCs with respect to the
possibility of tumour formation. Investigation of the long-term fate of
ADSCs is required before human trials could be considered, although
the lack of ADSCs in tissue sections observed for a 28-day follow-up
period implies that the potential of these cells to persist and undergo
malignant transformation is limited.124 Second, Garcia and co-work-
ers125 observed improved erectile function in type-2 diabetic rats after
autologous ADSC injection. This observation was based on decreased
numbers of apoptotic cells in the corpus cavernosum, increased num-
bers of sinusoid ECs and increased expression of nNOS in the penile
nerves. Because only a few of the prelabelled ADSCs were observed
within the corporal tissue of the treatment group, the authors sug-
gested that the treatment effect of the ADSCs may not be through
direct transformation into local cell types, but rather, via a more
‘indirect’ mechanism, whereby ADSCs improve the extracellular
environment and local tissue function within the treatment area.
The biggest shortcoming of this study is that the authors did not assess
the local retention or net survival of the injected ADSCs. How to
improve local retention of the transplanted ADSCs is a challenge for
cellular therapy. Improved local retention could lead to greater
improvement in erectile function after treatment. The use of bioab-
sorbable PLGA microspheres is a well-established means by which to
improve local retention, survival and possibly the therapeutic effect of
transplanted cells.126 Third, ADSCs and cell-free lysates derived from
ADSCs were injected into the penis in a rat model of cavernous nerve
injury, resulting in a significant recovery of erectile function in both
treatments compared with the control group.127 In the treated rats,
nNOS and smooth muscle content were preserved, and less fibrosis
occurred in the corpus cavernosum. The underlying mechanisms
involved neuron preservation and cytoprotection by inhibition of
apoptosis by releasing intracellular preformed substances or by active
secretion of certain biomolecules. However, the authors failed to
provide direct evidence to support the effects of a paracrine pathway.
Moreover, further investigations should be aimed to identify the
proteomic characteristics of the cell-free lysate. At last, CXCL5,
which is secreted in much larger amounts by ADSCs than by control
cells (penile smooth muscle cells),128 was discovered to be capable of
enhancing chemoattraction and angiogenesis,129 promoting rat
major pelvic ganglia neurite outgrowth, and activating the JAK/
STAT pathway in cultured Schwann cells.128 CXCL5 may thus con-
tribute to ADSCs’ therapeutic efficacy in cavernous nerve injury-
induced ED.
EPCs
While EPCs have been evaluated for predicting vasculogenic ED as
discussed above, there are few reports regarding the use of EPCs
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to treat ED. In 2010, Gou’s team130 investigated intracavernosal
injection of EPCs overexpressing VEGF. The results showed that
modified EPCs could restore the erectile function of rats with diabetic
ED by enhancing the expression of VEGF, facilitating the process of
neovascularisation and incorporating into the endothelium to
improve the function of ECs.
Umbilical cord blood stem cells (UCBSCs)
Umbilical cord blood is an important source of stem cells. UCBSCs are
deemed to be the newest and youngest among the stem cells. They also
avoid the debates surrounding ESCs because they can be obtained
without destroying an embryo. Moreover, UCBSCs do not possess
mutations in DNA, which are commonly found in ASCs.131 In 2010,
intracavernous transplantation of human UCBSCs was reported to
improve erectile function and blood glucose levels in patients with
diabetic ED without immune suppression.132 This study is the first
clinical report describing the use of unmodified stem cell therapy for
the treatment of diabetic ED. However, the exact mechanisms were
not elucidated and may involve as-yet-unidentified humoral factors
generated by the stem cells themselves. Moreover, the total cell num-
ber that was injected in the report was quite small relative to the unit
body weights compared with other studies, and the rates of implanta-
tion and differentiation of stem cells in the corpus cavernosa during
the follow-up remained unknown.
Brain-derived stem cells (BDSCs)
Previous work showed the remarkable plasticity of central nervous
system-derived stem cells; they have the capacity to give rise to large,
flat smoothmuscle-like cells that express phenotypic characteristics of
SMCs.133 In 2009, Song et al.134 injected foetal BDSCs labelled with
green fluorescent protein into penile tissue. Six weeks later, there was
evidence of transdifferentiation of BDSCs into penile SMCs as the
differentiated cells (30%–40%) expressed smooth muscle markers.
Although the demonstration of pluripotency and confirmation of
the expression of smooth muscle markers confirm that BDSCs are
worthy of further examination as a potential resource for penile
smooth muscle regeneration, clinical application will be limited
regarding the source of these cells.
Neural crest stem cells (NCSCs)
NCSCs are the progenitor cells of cell types constituting the peripheral
nervous system, including neurons, Schwann cells and adrenal chro-
maffin cells as well as SMCs.135 NCSCs are closely related to neural
tube cells, as both are descendants of the same higher order stem
cells.136 Importantly, similar to ASCs, intraspinal administration of
NCSCs did not result in the formation of tumours or teratomas.137
Many studies have shown that transplantation of NCSCs could induce
the regeneration of connective tissues, SMCs, skeletal muscle and
endothelium. In 2008, the feasibility of using human NCSCs for cor-
pus cavernosum repair and potential differentiation of NCSCs
into penile cavernous sinus ECs and SMCs was investigated.135
Histological analysis indicated that transplanted NCSCs could pos-
sibly differentiate into ECs and SMCs, as shown by their expression of
cell type-specific markers. However, we do not know whether NCSCs-
based cell therapy could compromise penile erectile function in vivo in
animals. Furthermore, the differentiation of human NCSCs is uncon-
vincing before excluding the effects of fusion between transplanted
cells and host cells. The critical limitation of NCSCs in clinical applica-
tion, similar to BDSCs, is the lack of a sufficient source of these donor
cells.
Glial restricted progenitor cells (GRPCs)
In 2011, Nout et al.138 delivered GRPCs into a rat model of spinal
cord injury, and they found that those animals regained some
autonomic functions, such as a similar number of erectile events
per 24 h compared to the control group, implying that GRPCs have
potential therapeutic efficacy in patients with ED associated with
spinal cord injury.
ESCs
Although ESCs demonstrate powerful differentiation potency,
research has lagged due to legal and ethical considerations. In 2004,
ESCs transfected with BDNF that had differentiated along a neuronal
cell line were injected into the corpus cavernosum and found to
improve cavernous nerve regeneration and functional erectile status
after bilateral crush injury in the rat.139 Stem cells may present a
cellular substrate at the lesion site to support axonal extension. In
addition, stem cells may not require a prolonged presence to function;
their mechanism of action may be through growth factor expression
(BDNF, NGF and neurotrophin-3),140 inhibition of demyelination
and as an initial lattice of cellular substrate.
PERSPECTIVES
Stem cells, especially the ASCs, are regarded as candidates for the
diagnosis and treatment of ED due to many factors. Stem cells possess
the potential to undergo long-term proliferation, self-renewal and
multipotent differentiation, and they can serve as a vehicle for the
release of neurotrophins, such as nerve growth factor, to repair
damage caused by diabetes or pelvic surgery.
In addition to using stem cells for treatment of ED, stem cells could
be used as a predictor for the diagnosis and progress of ED.
It is worth noting that except for the application of exogenous stem
cells, reawakening and mobilizing endogenous stem cells could allow
the prevention and treatment of ED in the near future.
Of note, while most of the literature cited in this review concerns
animal studies, increasing interest is being given to translation of the
observed results into clinical applications of stem cells. Positive and
encouraging results have been obtained with the use of BMSC, MDSC
and ADSC in various diseases.
With growing evidence from basic research on the use of stem cells
for treatment of ED, in 2010, the first clinical trial was conducted in
Korea.132 In this study, morning erection was restored within one
month in three patients and within 3 months in six patients.
However, despite having increased penile rigidity, none of the patients
was able to achieve vaginal penetration unless aided by taking silde-
nafil before coitus. In 2011, another clinical trial was carried out in
France with intracavernous BMSCs injected into patients with ED
post-prostatectomy. The transplanted stem cells were autologous
intracavernous bone marrow-mononucleated cells containing main-
ly MSCs, EPCs and HSCs (http://www.clinicaltrials.gov/ct2/show/
NCT01089387?term5stem6cell6and6ED&rank51). As stated above,
a significant proportion of preclinical studies investigating the effects of
stem cells on ED concern cavernous nerve injury-induced ED, a con-
dition that we observe almost solely after pelvic surgery for malignan-
cies. The application of stem cells in this condition poses the risk of
interaction between the stem cells and prostate tumour cell lines,141 and
it is difficult to predict the effects of this interaction in vivo. Thus, while
animal studies are promising, translation to clinical application requires
further study on how various types of stem cells and their secretions
interact with tumour cells.
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Furthermore, it remains largely unknown what the fate of the
majority of stem cells is after injection into experimental animals.
As investigators focus on penile changes after cellular therapy, the
effects that this therapy has on other, non-diseased organ tissues is
still a mystery in the field of sexual medicine. This issue warrants
further investigations before translating these results and applying
these cell types in human patients.
CONCLUSIONS
A broad range of stem cell sources has been investigated preclinically
and has shown a high potential in the treatment and prevention of ED
of various origins. While preclinical animal data are highly promising,
attention is needed to elucidate the mechanisms of action of stem cell
therapy for ED and the potential adverse events associated with stem
cell application before the translation to clinical application is
attempted.
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